Vaxiion Therapeutics
Vaxiion Therapeutics is dedicated to developing innovative cancer immunotherapies that safely and effectively reawaken the body's immune system to recognize, seek out, and destroy tumors. Their mission is to become an industry leader in this field, providing personalized treatment options for cancer patients. The company leverages a proprietary molecular delivery platform based on recombinant bacterial minicells (rBMCs) to develop advanced oncolytic immunotherapy agents, with a focus on VAX014, which is currently in early-stage clinical trials. Their approach emphasizes trust, transparency, and translating excellent science into improved patient outcomes.
Industries
Nr. of Employees
small (1-50)
Vaxiion Therapeutics
Patents
Ionizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use
US-11564953-B2
View DetailsTherapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
US-10919942-B2
View DetailsIonizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use
US-10124024-B2
View Details
Ionizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use
US-11564953-B2
View DetailsTherapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
US-10919942-B2
View DetailsIonizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use
US-10124024-B2
View DetailsProducts
VAX014
A tumor-targeted oncolytic immunotherapy based on a recombinant bacterial minicell delivery platform that combines integrin-targeting surface ligands, a pre-formed pore-forming oncolytic protein, and innate immune (STING/RIG-I) agonists for intratumoral or intravesical administration.
VAX014
A tumor-targeted oncolytic immunotherapy based on a recombinant bacterial minicell delivery platform that combines integrin-targeting surface ligands, a pre-formed pore-forming oncolytic protein, and innate immune (STING/RIG-I) agonists for intratumoral or intravesical administration.
Expertise Areas
- Cancer immunotherapy
- In situ immunization (intratumoral immunotherapy)
- Particle-based targeted drug delivery
- Preclinical tumor immunology and in vivo efficacy models
Key Technologies
- Recombinant bacterial minicell delivery platform
- Integrin-targeted cellular internalization
- Pore-forming oncolytic protein payloads
- STING and RIG-I pathway agonists
News & Updates
Vaxiion's 2025 publication in Molecular Cancer Therapeutics highlights that VAX014 co-stimulates the STING and RIG-I pathways, has optimal activity in tumors expressing these pathways, and is associated with better clinical outcomes.
Vaxiion's 2023 publication in The Journal for ImmunoTherapy of Cancer reports that VAX014 elicits tumor-specific T cell responses, activates multiple innate immune pathways, and shows synergy with immune checkpoint blockade.
Vaxiion's 2022 publication in Cancer Immunology Research demonstrates that VAX014 acts through in situ immunization, eliciting tumor-specific immune responses and synergizing with PD-(L)1 blockade.
Vaxiion's 2016 publication in Molecular Therapy - Oncolytics details the structure, integrin-specificity, and mechanism of VAX014, with efficacy data in bladder cancer models.
Vaxiion's 2025 publication in Molecular Cancer Therapeutics highlights that VAX014 co-stimulates the STING and RIG-I pathways, has optimal activity in tumors expressing these pathways, and is associated with better clinical outcomes.
Vaxiion's 2023 publication in The Journal for ImmunoTherapy of Cancer reports that VAX014 elicits tumor-specific T cell responses, activates multiple innate immune pathways, and shows synergy with immune checkpoint blockade.
Vaxiion's 2022 publication in Cancer Immunology Research demonstrates that VAX014 acts through in situ immunization, eliciting tumor-specific immune responses and synergizing with PD-(L)1 blockade.
Vaxiion's 2016 publication in Molecular Therapy - Oncolytics details the structure, integrin-specificity, and mechanism of VAX014, with efficacy data in bladder cancer models.